Scientific Advisory Board

To ensure the uniqueness, high-quality, and productivity of the Institute’s research on a long-term scale, the MBICR works with internationally recognized scientists from some of the world’s top research institutes and universities to review and steer the Institute’s research through its Scientific Advisory Board (SAB). The SAB also provides guidance and assistance in administrative policies and issues and help establish strong ties between the MBICR and the world-class research institutions overseas.? The SAB members are appointed by the Director of the MBICR after being approved by the SAB’s chair. The SAB is chaired by the Nobel Laureate Dr. J. Michael Bishop and also includes Dr. Kevan Shokat of UCSF (Medicinal Chemist), Dr. Scott Kogan of UCSF (Oncologist), Dr. Robert Lloyd FRS of University of Nottingham (Geneticist) and Dr. James Naismith FRS of University of Oxford (Structural Biologist). The SAB members frequently and carefully evaluate the work of the Institute. To keep the SAB informed promptly, the management team of the MBICR provides the SAB members four quarterly reports and one annual report each year. Every year, all SAB members will meet at the Institute in Chengdu in September or October for an annual performance review meanwhile the management team of the MBICR will meet the SAB members in the US and UK in April or May to deliver an interim report. Through this process, the MBICR promptly gains essential feedback on its work which can then inform future decisions.


Dr. J. Michael Bishop, Chairman of Scientific Advisory Board

Nobel laureate J. Michael Bishop, MD, chancellor emeritus of the University of California, San Francisco (UCSF), is one of the world’s foremost medical researchers, advisers, and teachers.?He shared the 1989 Nobel Prize in physiology or medicine with his UCSF colleague Dr. Harold Varmus, the former director of the National Institute of Health, United States. They won the award for the discovery of normal genes whose malfunction disposes cells to become cancerous. Their finding is widely credited with sparking a revolution in cancer research.?In 1981, Dr. Bishop became the director of the G. W. Hooper Research Foundation, which conducts multidisciplinary research on human disease.?He was appointed as University Professor in 1994, the highest honor that the University of California can bestow on a professor in recognition of superior scholarship and teaching.?Dr. Bishop became chancellor of UCSF in 1998.

Dr. Bishop has received numerous prestigious awards and honors in addition to the Nobel Prize.?He was appointed as Chair of the National Cancer Advisory Board by President Bill Clinton in 1994 and honored by President George Bush with the 2003 National Medal of Science, the nation’s highest honor for scientists.?Other honors and awards are exemplified by the Albert Lasker Basic Medical Research Award, the Armand Hammer Cancer Prize, and the Award for Distinguished Research in the Biomedical Sciences from the American Association of Medical Colleges.

Dr. Bishop is a member of several professional and honorary societies, including the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences, and the Royal Society.?Dr. Bishop has trained more than 300 Ph.D. students and postdoctoral scholars.?Many of them have arisen to elite positions in their institutes and become world-class experts in their research fields.?Dr. Bishop has coauthored nearly 400 research articles and reviews, and he is also the author of the book,?“How to win the Nobel Prize: An Unexpected Life in Science”.

Dr. Scott Kogan

Dr. Kogan is a Professor in the Department of Laboratory Medicine and the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. He is known as a world authority on the characterization and classification of hematopoietic neoplasms. As a board-certified hematopathologist, he has more than 20 years of experience in active practice diagnosing lymphomas, leukemias, and other hematologic disorders. Dr. Kogan is also a world-class researcher in the molecular pathogenesis of leukemia. He has so far co-authored more than 100 research articles. Dr. Kogan chaired the Hematopathology Subcommittee of the National Cancer Institute’s Mouse Models of Human Cancers Consortium and the Scientific Committee of Hematopathology & Clinical Laboratory Hematology, American Society of Hematology. He currently directs both UCSF Hematopathology and the mouse pathology core facility of the UCSF Cancer Center. Dr. Kogan received numerous professional awards such as the Burroughs Wellcome Fund Career Award, 32nd Edward Mallinckrodt Jr. Scholar Award, and the Leukemia & Lymphoma Society Scholar Award.

Professor Robert G. Lloyd

世界杯365bet下载365bet滚球注册365bet体育投注正规Professor Lloyd?is a fellow of The Royal Society of London and Professor of genetics in the School of Life Sciences at the University of Nottingham. He was appointed Head of the Department of Genetics at Nottingham and later directed the Institute of Genetics. Professor Lloyd?has been recognized worldwide for his contributions to the field of genome stability, and particularly to the dissection of the role of Holliday Junction processing systems RecG and RuvABC?in DNA recombination, replication and repair. Supported by major research funds from the UK Research Councils (MRC, BBSRC), The Wellcome Trust and The Royal Society, Professor Lloyd has so far trained 28 Ph.D. students and co-authored more than 180 research articles and reviews.? His inspiring studies have laid the foundation for understanding how genome integrity is maintained in normal cells and how genomic instability disorders such as cancer in human might arise when these processes go awry. Due to his landmark studies of the molecular basis of genome integrity, Professor Lloyd has been honoured with numerous awards such as Genome Stability Network Medal, Royal Society Fellowship, Royal Society Leverhulme Trust Senior Research Fellowship and Wellcome Trust Research Leave Fellowship.

Professor Lloyd?has shown an abiding commitment to public service in the scientific, academic and public policy areas. He has served on various scientific committees for The Royal Society and the UK Research Councils, has worked for the editorial boards for several scientific journals, and was appointed as an external assessor for Universities of Leeds, Glasgow, Bristol, Edinburgh, Leicester and York. He currently serves on The Royal Society Newton Advanced Fellowship Panel and on The Royal Society Sectional Committee.

Professor James H. Naismith

Professor James H. Naismith is a Fellow of the Royal Society and Professor of Structural Biology at the University of Oxford. He also directs the Research Complex at Harwell (CRaH), which is a Research Council UK (RCK) project led by Medical Research Council (MRC) and acts as the interim co-academic lead of the Rosalind Franklin Institute.

Professor Naismith has been recognized worldwide for his stunning structural and chemical dissection of the proteins involved in recognition, synthesis and export of natural compounds. Characterized by an integration of three-dimensional structural understanding with profound chemical insight, Professor Naismith’s research work has revealed new paradigms of nucleic acids and carbohydrates in cells, has illustrated novel biochemical mechanisms that enzymes catalyze nucleophilic substitution and addition reactions, and has produced the first structural and dynamic view of polysaccharide export systems in bacteria.

Funded by BBSRC, EPSRC, MRC, the Wellcome Trust, and the European Union, Professor Naismith has so far co-authored more than 240 research articles and reviews. Due to his landmark studies of protein structure and functions, Professor Naismith has been honored with numerous awards such as Colworth Medal, Corday Morgan Medal, Dextra Medal and Jeremy Knowles Medal. He was elected to the Royal Society of UK in 2014.

Professor Naismith’s insights and expertise in studying structures and functions of proteins and their interactions with natural compounds would be invaluable to the MBICR’s small-molecule drug design program and will strengthen the ability of MBICR to conduct structure-based design of innovative small-molecule drugs for the treatment of human cancer.

Dr. Kevan M. Shokat

Dr. Kevan M. Shokat is a professor and chair of the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and Professor of Chemistry at the University of California at Berkeley. He is also an investigator of the Howard Hughes Medical Institute.

Professor Shokat is a pioneer in the development of chemical methods for investigating cellular signal transduction pathways with a particular focus on protein kinases and lipid kinases. His laboratory uses a combination of chemical synthesis and protein engineering to create uniquely traceable and regulatable kinases, uncovering the function of more than 100 different kinases across all disease areas including oncology, metabolism, and infectious disease. Professor Shokat has received numerous awards for his work, including being named a Fellow of the Pew Foundation, Searle Foundation, Sloan Foundation, Glaxo-Wellcome Foundation, and the Cotrell Foundation.

He has also received the Eli Lilly Award in Biological Chemistry from American Chemical Society, Leslie Hellerman Lectureship from Johns Hopkins University, Chemical Science lectureship from Royal Society of Chemistry and Frank H. Westheimer Prize Lecture from Harvard University. He is a member of National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences

Professor Shokat is active in the development and commercialization of inventions made in his laboratory. He is a co-founder of Cellular Genomics Inc. and Intellikine. Multiple drugs developed in his lab are currently in clinical trials for the treatment of cancer. He also serves the Scientific Advisory Board for various companies such as Genentech, Invitrogen Corporation, Kara Oncology, Wellspring Biosciences, Blade Therapeutics, Xconomy, Mitokinin and California Institute for Biomedical Research.